Tharimmune reports positive phase 1 data on th104, its lead therapeutic candidate, for chronic pruritis in primary biliary cholangitis (pbc)

Phase 1 ex-us trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerability company expects to engage fda on phase 2 trial design and expects topline data in 2024 for chronic pruritis first indication for chronic pruritis in pbc where 70% of patients suffer from intractable and debilitating itching with limited treatment options bridgewater, nj / accesswire / november 27, 2023 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic conditions announces positive phase 1 data with th104, a proprietary transmucosal buccal film which easily adheres to the inside of the mouth. tharimmune also announced plans on a development timeline for a phase 2a study in chronic pruritis in primary biliary cholangitis (pbc) patients which will complement the data package the company expects to discuss with the us fda and european regulatory authorities.
THAR Ratings Summary
THAR Quant Ranking